BioSpace News Archive

2seventy bio, Inc. (Nasdaq: TSVT), announced today that it is transforming the Company to focus exclusively on the commercialization and development of Abecma (idecabtagene vicleucel), its BCMA-targeted CAR T therapy for multiple myeloma.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in The Journal of Thoracic and Cardiovascular Surgery demonstrating the ability of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to risk stratify and detect recurrence early in patients with resected stage I-II non-small cell lung cancer (NSCLC).

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results.

PolTREG S.A. announced that Prof. Piotr Trzonkowski, CEO, has co-authored a peer-reviewed article in Frontiers in Immunology, the world’s fifth most-cited immunology journal, laying out the decades of scientific progress underlying the company’s portfolio of ground-breaking clinical-stage therapies for diseases such as Type-1 Diabetes and Multiple Sclerosis.

VenomAid Diagnostics, the Danish company developing snakebite diagnostics, announced that it has successfully extended its seed round to $1.8 million with continued support from a select group of private Business Angels and the philanthropic venture fund Good Ventures LLC.

DP Technology, an “AI for Science” new paradigm-driven company, announced the nomination of DPT0218, a novel small molecule targeting Kv1.3, as a preclinical candidate compound for the treatment of various autoimmune diseases, including Inflammatory Bowel Disease and Atopic Dermatitis.

Singleron Biotechnologies announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length Transcriptome Library Kit.

EicOsis Human Health announced the next step in its ongoing human clinical trials: the initiation of Phase 1b multiple-ascending dose clinical trial to test the safety of its drug candidate, EC5026.

Delta-Fly Pharma Inc.: Update on the Interim Analysis Status of Phase III Study of DFP-10917 in the patients with R/R AML.

Vizient, Inc. projects drug price inflation to grow at 3.8% in the latest Pharmacy Market Outlook.